Please login to the form below

Not currently logged in

Eli Lilly demonstrates Verzenio win in high-risk breast cancer subset at ASCO

Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%

Eli Lilly has presented data for the potential new use of its CDK4/6 inhibitor Verzenio in high-risk early breast cancer patients at the 2021 American Society of Clinical Oncology (ASC) annual meeting.

An exploratory analysis of a prespecified subgroup of patients with HR-positive/HER2-negative high-risk early breast cancer who had received neoadjuvant chemotherapy showed that the addition of Verzenio (abemaciclib) to endocrine therapy (ET) decreased the risk of breast cancer recurrence in these patients by 38.6% compared to ET alone.

Verzenio plus ET also reduced the risk of patients developing metastatic disease by 39%, corresponding to a 6.7% difference in two-year distant relapse-free survival (DRFS) rates between the Verzenio treatment and control arms.

"People who receive neoadjuvant chemotherapy typically represent a patient population with a substantial risk of breast cancer recurrence. The data from monarchE further confirms this higher risk based on the number of events that occurred in the control arm for this subset of patients," said Maura Dickler, distinguished medical fellow, Lilly Oncology.

"Given the need for new treatments for high-risk early breast cancer, especially in this neoadjuvant population, it's encouraging to see these impressive results with a 38%  reduction in the risk of recurrence with the addition of Verzenio to standard endocrine therapy,” she added.

Previously, Lilly reported initial results from the monarchE trial, which showed that the Verzenio/ET combination reduced the risk of developing metastatic disease by 28 %, with the largest reductions occurring in rates of metastases to the liver and bone.

The monarchE trial is still ongoing, with patients continuing to be followed to assess the safety, overall survival and patient reported outcomes associated with Verzenio plus ET in high-risk early breast cancer patients.

Lilly also recently initiated a phase 3 trial – eMonarcHER – of Verzenio in combination with ET in patients with HR-positive/HER2-negative, node-positive, high-risk early breast cancer receiving adjuvant ET after completing surgery and neoadjuvant and/or adjuvant HER2 targeted therapy.

Article by
Lucy Parsons

7th June 2021

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...